{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:55:17Z","timestamp":1795100117093,"version":"4.10.3"},"reference-count":245,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1241450"],"award-info":[{"award-number":["1241450"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aohep.2025.101903","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:17:29Z","timestamp":1741900649000},"page":"101903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Updated recommendations for the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) by the Latin American working group"],"prefix":"10.1016","volume":"30","author":[{"given":"Luis Antonio","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Idalsoaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Perelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Dirchwolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javiera","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Samith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Val\u00e9rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Oliveira","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Brahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Castro-Narro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario G.","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10152","key":"10.1016\/j.aohep.2025.101903_bib0001","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101175","article-title":"The burden of liver disease in Latin America","volume":"29","author":"D\u00edaz","year":"2024","journal-title":"Ann Hepatol"},{"issue":"155958","key":"10.1016\/j.aohep.2025.101903_bib0003","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019","volume":"158","author":"Danpanichkul","year":"2024","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0004","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s13668-014-0104-4","article-title":"The intersection between food insecurity and diabetes: a review","volume":"3","author":"Gucciardi","year":"2014","journal-title":"Curr Nutr Rep"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"issue":"10440","key":"10.1016\/j.aohep.2025.101903_bib0006","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"10440","key":"10.1016\/j.aohep.2025.101903_bib0007","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101903_bib0008","series-title":"Global status report on alcohol and health and treatment of substance use disorders","year":"2024"},{"key":"10.1016\/j.aohep.2025.101903_bib0009","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0835","article-title":"Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021","author":"Danpanichkul","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100706","article-title":"Non-alcoholic fatty liver disease prevalence in Latin America: A Systematic review and meta-analysis","volume":"27","author":"Rojas","year":"2022","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0012","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(21)00279-5","article-title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","volume":"22","author":"Rumgay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2025.101903_bib0014","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2021.17","article-title":"Colorectal adenomas and MAFLD: a cross-sectional study in a hispanic screening cohort","author":"Villal\u00f3n","year":"2022","journal-title":"Metabol Target Organ Damage"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35511","article-title":"New-onset age of nonalcoholic fatty liver disease and cancer risk","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0017","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0018","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.aohep.2025.101903_bib0019","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0020","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/dar.13286","article-title":"The role of alcohol use in the aetiology and progression of liver disease: a narrative review and a quantification","volume":"40","author":"Rehm","year":"2021","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0021","doi-asserted-by":"crossref","first-page":"e0192","DOI":"10.1097\/CLD.0000000000000192","article-title":"Impact of alcohol use on liver disease outcomes","volume":"23","author":"Desalegn","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.aohep.2025.101903_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","author":"D\u00edaz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0024","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/liv.16034","article-title":"Metabolic characteristics of patients with MetALD: caveats of a new definition","volume":"44","author":"Petrie","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.101903_bib0025","article-title":"Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study","author":"Tavaglione","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2025.101903_bib0026","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","author":"Arab","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0027","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0028","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.20517\/mtod.2022.14","article-title":"Effect of cofactors on NAFLD\/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction","volume":"2","author":"Lonardo","year":"2022","journal-title":"Metab Target Organ Damage"},{"issue":"39","key":"10.1016\/j.aohep.2025.101903_bib0030","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.1113359108","article-title":"Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease","volume":"108","author":"Kumashiro","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.aohep.2025.101903_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0032","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0033","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0034","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol Med"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0036","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-\u03b1 and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0037","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0038","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0039","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2025.101903_bib0040","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","author":"Saeed","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0041","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors","volume":"21","author":"Rodriguez-Duque","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-med-051215-031109","article-title":"Nonalcoholic steatohepatitis","volume":"68","author":"Suzuki","year":"2017","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0043","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0041-1730927","article-title":"Insights into nonalcoholic fatty-liver disease heterogeneity","volume":"41","author":"Arrese","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2025.101903_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-332917","article-title":"Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA","author":"Yang","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0046","first-page":"404","article-title":"Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis","volume":"34","author":"Cholongitas","year":"2021","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0047","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0048","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.101903_bib0049","first-page":"1","article-title":"Liver diseases in Latin America: current status, unmet needs, and opportunities for improvement","author":"D\u00edaz","year":"2022","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","article-title":"Disparities in steatosis prevalence in the United States by race or ethnicity according to the 2023 criteria","volume":"4","author":"D\u00edaz","year":"2024","journal-title":"Commun Med"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0051","first-page":"721","article-title":"High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients","volume":"15","author":"Arab","year":"2016","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101111","article-title":"Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina","volume":"28","author":"Villamil","year":"2023","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0053","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1665-2681(19)31584-4","article-title":"Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile","volume":"10","author":"Cotrim","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0054","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","year":"2024","journal-title":"J Hepatol"},{"issue":"37","key":"10.1016\/j.aohep.2025.101903_bib0055","doi-asserted-by":"crossref","first-page":"e12356","DOI":"10.1097\/MD.0000000000012356","article-title":"Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus","volume":"97","author":"Zhao","year":"2018","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0056","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.aohep.2025.101903_bib0057","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162513","article-title":"Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease","volume":"132","author":"Tamaki","year":"2022","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0058","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.32510","article-title":"Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?","volume":"76","author":"Oliveira","year":"2022","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0059","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0060","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.aohep.2025.101903_bib0061","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.3350\/cmh.2022.0362","article-title":"Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: current and future developments","volume":"29","author":"Ahn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0062","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241276334","article-title":"Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques","volume":"17","author":"Hudson","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0063","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.101903_bib0064","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.24356","article-title":"Fatty liver index and mortality: the Cremona study in the 15th year of follow-up","volume":"54","author":"Calori","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.101903_bib0066","doi-asserted-by":"crossref","unstructured":"Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The Fatty liver Index (FLI) 15 years later: a reappraisal. Metabolism and Target Organ Damage [Internet]. 2021; Available from: https:\/\/doi.org\/10.20517\/mtod.2021.08","DOI":"10.20517\/mtod.2021.08"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0067","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0068","article-title":"The imaging techniques and diagnostic performance of ultrasound, CT, and MRI in detecting liver steatosis and fat quantification: a systematic review","volume":"16","author":"Wan","year":"2023","journal-title":"J Radiat Res Appl Sci"},{"key":"10.1016\/j.aohep.2025.101903_bib0069","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2021.05","article-title":"Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies","author":"Ballestri","year":"2021","journal-title":"Metabol Target Organ Damage"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.14309\/ajg.0000000000002020","article-title":"A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis","volume":"118","author":"Lee","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0071","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0072","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1478-3231.2012.02804.x","article-title":"Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD","volume":"32","author":"Ballestri","year":"2012","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0073","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0074","article-title":"Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease","author":"Turankova","year":"2020","journal-title":"Cochrane Libr"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0075","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0076","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","article-title":"The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis","volume":"21","author":"Bohte","year":"2011","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0077","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0078","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.numecd.2022.12.010","article-title":"Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent","volume":"33","author":"Colosimo","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0079","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","article-title":"Cigarette smoking and liver diseases","volume":"77","author":"Marti-Aguado","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0081","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0082","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0083","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0084","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0085","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0086","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.aohep.2020.08.066","article-title":"Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population","volume":"19","author":"Zambrano-Huailla","year":"2020","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0087","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0088","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0089","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrgastro.2016.86","article-title":"Critical comparison of elastography methods to assess chronic liver disease","volume":"13","author":"Friedrich-Rust","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0091","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jhep.2011.10.017","article-title":"Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan\u00ae","volume":"56","author":"de L\u00e9dinghen","year":"2012","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0092","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0093","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jmri.23731","article-title":"Magnetic resonance elastography of liver: technique, analysis, and clinical applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0094","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/MEG.0000000000000846","article-title":"Two-dimensional shear-wave elastography: a new method comparable to acoustic radiation force impulse imaging?","volume":"29","author":"Schellhaas","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0096","article-title":"Disparities in screening and risk stratification for hispanic adults with metabolic dysfunction-associated steatotic liver disease","author":"Tincopa","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0097","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0098","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0099","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.11.009","article-title":"Using NIS2+TM to identify at-risk MASH in clinical trials","volume":"80","author":"Lai","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0101","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.34221","article-title":"Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0102","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0103","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/hep4.1976","article-title":"NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population","volume":"6","author":"Thomas","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0104","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/apt.18099","article-title":"The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes","volume":"60","author":"Bridi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0106","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0108","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.13435","article-title":"The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms","volume":"37","author":"Zelber-Sagi","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0109","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/nu17010143","article-title":"Dietary influences on gut microbiota and their role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Hamamah","year":"2024","journal-title":"Nutrients"},{"issue":"25","key":"10.1016\/j.aohep.2025.101903_bib0111","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dsi23-0009","article-title":"Practical lifestyle management of nonalcoholic fatty liver disease for busy clinicians","volume":"37","author":"Zelber-Sagi","year":"2024","journal-title":"Diabetes Spectr"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0113","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/s-0041-1729971","article-title":"Treatment for NAFLD: new clinical and epidemiological evidence and updated recommendations","volume":"41","author":"Dietary","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.aohep.2025.101903_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies","volume":"20","author":"Hayat","year":"2021","journal-title":"Ann Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0115","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0116","doi-asserted-by":"crossref","first-page":"e0044","DOI":"10.1097\/HC9.0000000000000044","article-title":"Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis","volume":"7","author":"DiBattista","year":"2023","journal-title":"Hepatol Commun"},{"issue":"13","key":"10.1016\/j.aohep.2025.101903_bib0117","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13133772","article-title":"Leisure-time physical activity in subjects with metabolic-dysfunction-associated steatotic liver disease: an all-cause mortality study","volume":"13","author":"Curci","year":"2024","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0118","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0119","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","article-title":"Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"14","author":"Xue","year":"2024","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.aohep.2025.101903_bib0120","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0121","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3748\/wjg.v30.i7.636","article-title":"Muscle strength and non-alcoholic fatty liver disease\/metabolic-associated fatty liver disease","volume":"30","author":"Hao","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2025.101903_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00380-7","article-title":"Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective","author":"D\u00edaz","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0124","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11901-023-00629-0","article-title":"Emerging drug therapies for metabolic dysfunction-associated steatotic liver disease: a glimpse into the horizon","volume":"23","author":"Arnold","year":"2024","journal-title":"Curr Hepatol Rep"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0125","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.cell.2024.05.009","article-title":"Resmetirom for treatment of MASH","volume":"187","author":"Sookoian","year":"2024","journal-title":"Cell"},{"issue":"10213","key":"10.1016\/j.aohep.2025.101903_bib0126","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0127","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0128","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2025.101903_bib0129","doi-asserted-by":"crossref","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty Liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023 May;19(1):60\u201370. Available from: https:\/\/doi.org\/10.17925\/EE.2023.19.1.60","DOI":"10.17925\/EE.2023.19.1.60"},{"key":"10.1016\/j.aohep.2025.101903_bib0130","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000551","article-title":"Thyroid hormone action and liver disease, a complex interplay","author":"Marino","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0131","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.31296","article-title":"Thyroid hormone signaling and the liver","volume":"72","author":"Ritter","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0132","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1-2","key":"10.1016\/j.aohep.2025.101903_bib0133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0134","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11-12","key":"10.1016\/j.aohep.2025.101903_bib0135","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2025.101903_bib0136","series-title":"Presented at: The Liver Meeting; November 15-19","article-title":"Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) [AASLD abstract 5018]","author":"Newsome","year":"2024"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0137","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10019","key":"10.1016\/j.aohep.2025.101903_bib0138","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0139","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0141","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0142","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2025.101903_bib0144","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0145","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0146","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2025.101903_bib0147","article-title":"New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease","author":"Diaz","year":"2023","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.aohep.2025.101903_bib0148","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0149","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0150","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of Saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0151","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0152","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.aohep.2025.101903_bib0153","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"10215","key":"10.1016\/j.aohep.2025.101903_bib0154","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0156","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0157","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0158","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of Aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0161","article-title":"A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0162","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0163","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101903_bib0164","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S2468-1253(23)00285-6","article-title":"Efruxifermin in non-alcoholic steatohepatitis","volume":"8","author":"Mahgoub","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0165","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0166","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMe2307249","article-title":"Pegozafermin for NASH - a sprint to start a marathon","volume":"389","author":"Rinella","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0167","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0168","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0169","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0170","doi-asserted-by":"crossref","unstructured":"Radosavljevic T, Brankovic M, Samardzic J, Djureti\u0107 J, Vukicevic D, Vucevic D, et al. Altered mitochondrial function in MASLD: key features and promising therapeutic approaches. Antioxidants (Basel). 2024 Jul 26;13(8):906. Available from: https:\/\/doi.org\/10.3390\/antiox13080906","DOI":"10.3390\/antiox13080906"},{"issue":"18","key":"10.1016\/j.aohep.2025.101903_bib0171","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.aohep.2025.101903_bib0172","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1158\/1055-9965.EPI-09-0013","article-title":"Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy trial","volume":"18","author":"Neuhouser","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0173","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0174","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0176","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0177","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.aohep.2025.101903_bib0178","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol"},{"issue":"29","key":"10.1016\/j.aohep.2025.101903_bib0179","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2174\/1381612827666210315144821","article-title":"The effect of metformin on aminotransferase levels, metabolic parameters and body mass index in nonalcoholic fatty liver disease patients: a metaanalysis","volume":"27","author":"Hu","year":"2021","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0180","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2025.101903_bib0181","first-page":"S52","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0182","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0183","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0184","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MEG.0000000000002877","article-title":"Navigating the landscape of metabolic-associated steatotic liver disease treatment: aspirin as a potential game changer","volume":"37","author":"Narang","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.aohep.2025.101903_bib0186","article-title":"Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery","author":"Feng","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"20","key":"10.1016\/j.aohep.2025.101903_bib0187","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"10390","key":"10.1016\/j.aohep.2025.101903_bib0188","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0189","first-page":"119","article-title":"Acute liver failure after bariatric surgery","volume":"1","author":"Onem","year":"2020","journal-title":"Hepatol Forum"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0190","doi-asserted-by":"crossref","first-page":"755","DOI":"10.21037\/hbsn-22-386","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective","volume":"11","author":"D\u00edaz","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"10360","key":"10.1016\/j.aohep.2025.101903_bib0191","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101903_bib0192","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: insights in epidemiology, pathogenesis, imaging, prevention and therapy","volume":"93","author":"Polyzos","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0193","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/apt.17371","article-title":"Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin","volume":"57","author":"Zeng","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0194","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0195","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.aohep.2025.101903_bib0196","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0197","first-page":"e563","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0198","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0199","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.aohep.2025.101903_bib0200","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1097\/QAD.0000000000001483","article-title":"Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver","volume":"31 Suppl 2","author":"Guaraldi","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0201","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1038\/s41598-023-32965-y","article-title":"Metabolic dysfunction-associated fatty liver disease in people living with HIV","volume":"13","author":"Michel","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0202","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12944-024-02317-4","article-title":"MASLD in persons with HIV is associated with high cardiometabolic risk as evidenced by altered advanced lipoprotein profiles and targeted metabolomics","volume":"23","author":"Lin","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.aohep.2025.101903_bib0203","article-title":"Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis","volume":"11","author":"Jin","year":"2023","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0204","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/apt.18236","article-title":"MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls","volume":"60","author":"Allende","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.aohep.2025.101903_bib0205","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.cgh.2024.03.028","article-title":"Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma","volume":"22","author":"Rivera-Esteban","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0206","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.aohep.2025.101903_bib0207","doi-asserted-by":"crossref","DOI":"10.20517\/mtod.2021.03","article-title":"Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?","author":"Lonardo","year":"2021","journal-title":"Metabol Target Organ Damage"},{"key":"10.1016\/j.aohep.2025.101903_bib0208","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0209","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/hep.32016","article-title":"Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multinational study","volume":"74","author":"D\u00edaz","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2025.101903_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(22)00008-5","article-title":"The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas","author":"D\u00edaz","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0211","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0212","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","author":"D\u00edaz","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0213","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100359","article-title":"NAFLD: challenges and opportunities to address the public health problem in Latin America","volume":"24","author":"Arab","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0214","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00220-6","article-title":"Best buy interventions to address the burden of steatotic liver disease","author":"Lazarus","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2025.101903_bib0215","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jhep.2023.08.019","article-title":"Prevalence of steatotic liver disease and associated fibrosis in the United States: results from NHANES 2017-March 2020","volume":"80","author":"Luo","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2025.101903_bib0217","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0218","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111648","article-title":"Epidemiology of NAFLD - focus on diabetes","volume":"210","author":"Younossi","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0219","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0220","first-page":"4","article-title":"Fibrosis assessment in patients with nonalcoholic fatty liver disease: adherence to proposed algorithms and barriers to complying with them","volume":"87","author":"Marciano","year":"2022","journal-title":"Rev Gastroenterol Mex"},{"issue":"21","key":"10.1016\/j.aohep.2025.101903_bib0221","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.21037\/atm-20-2951","article-title":"Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance","volume":"8","author":"Jeong","year":"2020","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0222","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0223","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.14172","article-title":"Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population","volume":"46","author":"Yip","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2025.101903_bib0224","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2017.09.020","article-title":"NAFL screening score: a basic score identifying ultrasound-diagnosed non-alcoholic fatty liver","volume":"475","author":"Zhou","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.aohep.2025.101903_bib0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-5926-4-10","article-title":"The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis","volume":"4","author":"Poynard","year":"2005","journal-title":"Comp Hepatol"},{"issue":"40","key":"10.1016\/j.aohep.2025.101903_bib0226","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","article-title":"Ultrasound-based techniques for the diagnosis of liver steatosis","volume":"25","author":"Ferraioli","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0227","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101903_bib0228","article-title":"Magnetic resonance spectroscopy of hepatic fat from fundamental to clinical applications","volume":"11","author":"Pasanta","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0229","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2010.01.008","article-title":"Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations","volume":"52","author":"Lee","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101903_bib0231","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0232","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0233","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","author":"Loaeza-del-Castillo","year":"2008","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0234","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0235","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0236","article-title":"Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0237","article-title":"The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease","volume":"10","author":"Chimoriya","year":"2020","journal-title":"J Clin Med Res"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0238","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/liv.14084","article-title":"MACK-3 (combination of hoMa, Ast and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis","volume":"39","author":"Chuah","year":"2019","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.aohep.2025.101903_bib0239","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.aohep.2025.101903_bib0240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2025.101903_bib0241","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+TM, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101903_bib0242","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101903_bib0243","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemp Clin Trials"},{"issue":"3-4","key":"10.1016\/j.aohep.2025.101903_bib0244","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"issue":"7","key":"10.1016\/j.aohep.2025.101903_bib0245","first-page":"45","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed Pract"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125001279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:35:03Z","timestamp":1764668103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":245,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1665268125001279"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101903","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated recommendations for the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) by the Latin American working group","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101903"}}